Theralase Technologies Inc.

DB:TTX Stock Report

Market Cap: €44.4m

Theralase Technologies Management

Management criteria checks 3/4

Theralase Technologies' CEO is Roger Dumoulin-White, appointed in May 2023, has a tenure of 1.67 years. total yearly compensation is CA$405.00K, comprised of 98.8% salary and 1.2% bonuses, including company stock and options. directly owns 4.64% of the company’s shares, worth €2.06M. The average tenure of the management team and the board of directors is 14.4 years and 6.6 years respectively.

Key information

Roger Dumoulin-White

Chief executive officer

CA$405.0k

Total compensation

CEO salary percentage98.8%
CEO tenure1.7yrs
CEO ownership4.6%
Management average tenure14.4yrs
Board average tenure6.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Roger Dumoulin-White's remuneration changed compared to Theralase Technologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CA$4m

Jun 30 2024n/an/a

-CA$4m

Mar 31 2024n/an/a

-CA$4m

Dec 31 2023CA$405kCA$400k

-CA$5m

Sep 30 2023n/an/a

-CA$4m

Jun 30 2023n/an/a

-CA$5m

Mar 31 2023n/an/a

-CA$5m

Dec 31 2022n/an/a

-CA$5m

Sep 30 2022n/an/a

-CA$6m

Jun 30 2022n/an/a

-CA$5m

Mar 31 2022n/an/a

-CA$5m

Dec 31 2021n/an/a

-CA$4m

Sep 30 2021n/an/a

-CA$4m

Jun 30 2021n/an/a

-CA$4m

Mar 31 2021n/an/a

-CA$5m

Dec 31 2020n/an/a

-CA$6m

Sep 30 2020n/an/a

-CA$8m

Jun 30 2020n/an/a

-CA$8m

Mar 31 2020n/an/a

-CA$8m

Dec 31 2019n/an/a

-CA$7m

Sep 30 2019n/an/a

-CA$5m

Jun 30 2019n/an/a

-CA$4m

Mar 31 2019n/an/a

-CA$3m

Dec 31 2018CA$301kCA$300k

-CA$3m

Compensation vs Market: Roger's total compensation ($USD281.23K) is below average for companies of similar size in the German market ($USD465.04K).

Compensation vs Earnings: Roger's compensation has increased whilst the company is unprofitable.

CEO

Roger Dumoulin-White

1.7yrs

Tenure

CA$405,000

Compensation

Mr. Roger John Dumoulin-White, B.Sc., P.Eng., Pro. Dir., is President, Chief Executive Officer and Director of Theralase Technologies Inc. from May 2023. He joined the Theralase Technologies Inc. in 2003....

Leadership Team

NamePositionTenureCompensationOwnership
Roger Dumoulin-White
President1.7yrsCA$405.00k4.64%
€ 2.1m
Kristina Hachey
CFO & Director20.7yrsCA$260.00k1.22%
€ 544.0k
Arkady Mandel
Chief Scientific Officer & Director13.9yrsCA$310.00k0.12%
€ 53.6k
David Groves
President of World Trade Division18.2yrsno datano data
Terry Ruch
Equine Medical Consultant14.4yrsno datano data

14.4yrs

Average Tenure

Experienced Management: TTX's management team is seasoned and experienced (14.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Roger Dumoulin-White
President1.7yrsCA$405.00k4.64%
€ 2.1m
Kristina Hachey
CFO & Director5.6yrsCA$260.00k1.22%
€ 544.0k
Arkady Mandel
Chief Scientific Officer & Director6.6yrsCA$310.00k0.12%
€ 53.6k
Randy Bruder
Independent Director17yrsCA$10.00k0.75%
€ 334.9k
Matthew Perraton
Independent Chairman of the Board11.9yrsCA$10.00k0.021%
€ 9.1k
Guy Anderson
Independent Director11.9yrsCA$10.00k0.090%
€ 40.1k
Ashish Kamat
Member of Medical & Scientific Advisory Board10.1yrsno datano data
Michael O'Donnell
Member of Medical & Scientific Advisory Board2yrsno datano data
Kaouthar Lbiati
Independent Director1.6yrsCA$45.13k0.0040%
€ 1.8k

6.6yrs

Average Tenure

Experienced Board: TTX's board of directors are considered experienced (6.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 10:33
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Theralase Technologies Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas LoeEchelon Wealth Partners Inc.
Andre UddinResearch Capital Corporation